Home > Riviste > Minerva Biotecnologica > Fascicoli precedenti > Minerva Biotecnologica 2003 June;15(2) > Minerva Biotecnologica 2003 June;15(2):161-6

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA BIOTECNOLOGICA

Rivista di Biologia Molecolare e Biotecnologie


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,25


eTOC

 

ORIGINAL ARTICLES  TRENDS IN MOLECULAR DIAGNOSIS AND THERAPY OF β-THALASSEMIA AND SICKLE CELL ANEMIAFREEfree


Minerva Biotecnologica 2003 June;15(2):161-6

Copyright © 2003 EDIZIONI MINERVA MEDICA

lingua: Inglese

The orphan medicinal products: an international challenge

Meyers A. 1, Lipucci di Paola M. 2

1 National Organization for Rare Disorders (NORD), Danbury, CT, USA; 2 European Organization for Rare Disorders (EURORDIS), Paris, France


FULL TEXT  


Here we analyse the American experience on the Orphan Medicinal Products together with the European one. In particular, we considered the procedures for Orphan designation and development, the availability of financial resources and incentive measures for the development, the access and availability of orphan medicines designated and authorized for the market, the role of patients’ representatives, the legislation and health policies. The great challenge in the near future is expected to be the improvement of trans-national cooperation and the building of an active and international community able to act and address the economic and intellectual efforts towards the concrete solutions of the priorities, including information, development, access, availability of therapies for rare diseases over the national borders.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail